Methods and compositions for modulating lymphangiogenesis, e.g., to treat transplant rejection, in a subject
Patent Number: US9364535
Executive Summary:
General Description:
This invention provides a novel method of modulating the occurrence of lymphangiogenesis in a subject by administering to the subject an amount of: a first antagonist for VEGFR-3, wherein the first antagonist is a neutralizing antibody or binding fragment thereof that specifically binds to VEGFR-3; and a second antagonist for VLA-1, wherein the second antagonist is a neutralizing antibody or binding fragment thereof that specifically binds to VLA-1; and has been shown to be effective to reduce the occurrence of lymphangiogenesis in a corneal transplant in the subject having a high risk of rejection.
Strengths:
Weaknesses:
Patent Status:
Inventor Bio: Lu Chen
https://optometry.berkeley.edu/people/lu-chen-md-phd/
Executive Summary:
- Invention Type: Therapeutic
- Patent Status: Issued (Grant date: 2016-06-14)
- Patent Link: https://patents.google.com/patent/US9364535
- Research Institute: University of California, Berkeley
- Disease Focus: Corneal transplantations
- Basis of Invention: Inhibitors blocking VEGF receptors and integrin receptor are potent inhibitors not only of inflammatory corneal hemangiogenesis, but also lymphangiogenesis in vivo
- How it works: Administering to the subject an effective amount of a first antagonist for a tyrosine kinase receptor and an effective amount of a second antagonist for an integrin receptor
- Lead Challenge Inventor: Inhibitors that have been developed against lymphangiogenic growth factors and their receptors
- Inventors: Chen; Lu (Berkeley, CA)
- Development Stage: in vivo data (mice), preclinical
- Novelty: Combination of chemicals used is novel (in the case of corneal transplantations)
- Clinical Applications: Corneal transplantations
General Description:
This invention provides a novel method of modulating the occurrence of lymphangiogenesis in a subject by administering to the subject an amount of: a first antagonist for VEGFR-3, wherein the first antagonist is a neutralizing antibody or binding fragment thereof that specifically binds to VEGFR-3; and a second antagonist for VLA-1, wherein the second antagonist is a neutralizing antibody or binding fragment thereof that specifically binds to VLA-1; and has been shown to be effective to reduce the occurrence of lymphangiogenesis in a corneal transplant in the subject having a high risk of rejection.
Strengths:
- The combination of inhibitors used is new
Weaknesses:
- Has not been tested in humans yet
Patent Status:
- Priority date: 2012-08-15
- Filing date: 2013-08-14
- Publication date: 2016-06-14
- Grant date: 2016-06-14
Inventor Bio: Lu Chen
https://optometry.berkeley.edu/people/lu-chen-md-phd/
